Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Beginning in 2023, five years after their European counterparts, ...
UnitedHealth Group, Inc’s. UNH Optum Rx is expanding its offerings for patients with the introduction of two additional HUMIRA biosimilars. Effective Jul 1, Optum Rx will offer three biosimilar ...
AbbVie Inc. (ABBV) is a US-based biopharmaceutical company formed in 2013 as a spinoff from Abbott Laboratories (ABT). It’s a cutting-edge company with strong exposure to high-demand needs in ...
Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results